文献速递遗传性与小管间质肾病慢性肾脏病

近端小管病的药物发现与治疗前景

Drug discovery and therapeutic perspectives for proximal tubulopathies.
PubMed 文献 · Kidney Int · 2023-09-30

本综述以遗传性近端小管病为肾脏稳态障碍的范式,讨论肾小管功能障碍的机制,并概述用于识别可干预靶点的药物发现方法及潜在治疗药物的临床前管线,旨在推动 academia-industry 合作以加速知识向创新疗法的转化。

要点

  • 近端小管上皮细胞对必需营养物的高效重吸收依赖囊泡运输网络,溶酶体是处理 incoming 分子、感知营养可用性、分选受体与转运体及平衡分化和增殖的核心。
  • 这些基本过程紊乱可导致近端小管病,特征为肾小管细胞功能障碍并出现尿中低分子量蛋白和溶质。
  • 若未治疗,近端小管病可进展为慢性肾脏病和严重并发症。

核心结论

  • 对影响近端小管的罕见遗传病的功能研究为稳态基本机制提供了可操作的见解,并揭示了用于治疗发现和开发的药物靶点。
  • 这些努力可能最终为近端小管病带来新的治疗途径,而现有疗法目前对这些疾病处理不充分。

研究设计与样本

  • 本综述以遗传性近端小管病作为肾脏稳态障碍的范式进行探讨,讨论导致肾小管功能障碍的因素,并概述当前用于识别可操作靶点的药物发现方法及潜在治疗药物的临床前管线。

主要发现

  • 近端小管上皮细胞对必需营养物的高效重吸收依赖囊泡运输通路构成的复杂生态系统,溶酶体在该网络中发挥核心作用。
  • 这些基本过程紊乱可导致近端小管病,其特征为肾小管细胞功能障碍并出现尿中低分子量蛋白和溶质。
  • 若未治疗,近端小管病可进展为慢性肾脏病和严重并发症。

临床怎么用

  • 本综述旨在促进学术界与产业界的合作,并倡导建立研究联盟,以加速将知识进展有效转化为创新疗法,满足这些衰弱性疾病患者巨大的未满足需求。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficient reabsorption of essential nutrients by epithelial cells in the proximal tubule of the kidney is crucial for maintaining homeostasis. This process relies heavily on a complex ecosystem of vesicular trafficking pathways. At the center of this network, the lysosome plays a pivotal role in processing incoming molecules, sensing nutrient availability, sorting receptors and transporters, and balancing differentiation and proliferation in the tubular epithelial cells. Disruptions in these fundamental processes can lead to proximal tubulopathy-a condition characterized by the dysfunction of the tubular cells followed by the presence of low-molecular-weight proteins and solutes in urine. If left untreated, proximal tubulopathy can progress to chronic kidney disease and severe complications. Functional studies of rare inherited disorders affecting the proximal tubule have gleaned actionable insights into fundamental mechanisms of homeostasis while revealing drug targets for therapeutic discovery and development. In this mini review, we explore hereditary proximal tubulopathies as a paradigm of kidney homeostasis disorders, discussing the factors contributing to tubular dysfunction. In addition, we shed light on the current landscape of drug discovery approaches used to identify actionable targets and summarize the preclinical pipeline of potential therapeutic agents. These efforts may ultimately lead to new treatment avenues for proximal tubulopathies, which are currently inadequately tackled by existing therapies. Through this article, our hope is to promote academia-industry partnerships and advocate for research consortia that can accelerate the effective translation of knowledge advances into innovative therapies addressing the huge unmet needs of individuals with these debilitating diseases.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Keller SA, Chen Z, Gaponova A, et al. Drug discovery and therapeutic perspectives for proximal tubulopathies. Kidney Int. 2023. PMID: 37783447. doi:10.1016/j.kint.2023.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。